Oldenburg in Holstein
Oldenburg in Holstein
Oldenburg in Holstein, Germany10 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Phase 2 | 2026-10-07 | NCT04486378 | |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Nutritional and Metabolic Diseases, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypertensive disorder, metabolic disease, type 2 diabetes mellitus, vascular disorder | Recruiting | Phase 3 | 2026-09-30 | NCT07064473 | |
| AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-09-11 | NCT07503210 | |
| REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | cardiovascular disorder | Active, not recruiting | Phase 3 | 2026-08-31 | NCT05669755 | |
| Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-08-06 | NCT07220642 | |
| Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS) | Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitus | Active, not recruiting | Phase 2 | 2026-06-29 | NCT06111586 | |
| Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients | primary central nervous system lymphoma | Recruiting | Phase 3 | 2025-02-17 | NCT06830421 | |
| Fosfomycin I.v. for Treatment of Severely Infected Patients | Bacterial Infections and Mycoses, Bone Diseases, Infectious, Brain Abscess, Cardiovascular Infections, Central Nervous System Bacterial Infections, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Infections, Inflammation, Intraabdominal Infections, Male Urogenital Diseases, Neuroinflammatory Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Skin and Connective Tissue Diseases, Soft Tissue Infections, Suppuration, Systemic Inflammatory Response Syndrome, Urogenital Diseases, abscess, bacterial endocarditis, bacterial infectious disease, bacterial infectious disease with sepsis, bacterial meningitis, bacterial pneumonia, bone disorder, brain disorder, cardiovascular disorder, central nervous system disorder, central nervous system infectious disorder, encephalitis, endocarditis, gram-negative bacterial infections, gram-positive bacterial infections, heart disorder, lung disorder, meningitis, musculoskeletal system disorder, nervous system disorder, osteomyelitis, pneumonia, respiratory system disorder, respiratory tract infectious disorder, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, urinary system disorder, urinary tract infection | Recruiting | Not stated | 2024-10-01 | NCT02979951 | |
| Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2024-06-04 | NCT05202509 | |
| BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Not stated | 2022-09-29 | NCT04673955 |